STOCK TITAN
  1. Home
  2. Sec-filings
  3. NERV
  4. [ARS] Minerva Neurosciences, Inc. SEC Filing

[ARS] Minerva Neurosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS
ARS - Minerva Neurosciences, Inc.

ARS Filing - Minerva Neurosciences, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Minerva Neurosciences, Inc. (NERV)

Acceptance Date: 2025-11-24T16:07:53.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Stock NERV logo
Minerva Neurosci

NASDAQ:NERV

NERV Rankings

#4520 Ranked by Market Cap
N/A Ranked by Dividends

NERV Latest News

Nov 19, 2025
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Nov 5, 2025
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Oct 21, 2025
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Aug 14, 2025
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
May 13, 2025
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

NERV Latest SEC Filings

Nov 24, 2025
[DEF 14A] Minerva Neurosciences, Inc. Definitive Proxy Statement
Nov 19, 2025
[8-K] Minerva Neurosciences, Inc. Reports Material Event
Nov 18, 2025
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity
Nov 18, 2025
[Form 3] Minerva Neurosciences, Inc. Initial Statement of Beneficial Ownership
Nov 5, 2025
[10-Q] Minerva Neurosciences, Inc. Quarterly Earnings Report

NERV Stock Data

184.78M
5.44M
22.26%
27.99%
0.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGTON